Nautilus Biotechnology (NAUT) Capital Expenditures (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Capital Expenditures of $454000.0 for Q2 2026, down 10.98% sequentially from $510000.0 in Q1 2026, and up 14.65% YoY from $396000.0 in Q2 2025.
Nautilus Biotechnology (NAUT) Capital Expenditures (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Capital Expenditures for 7 years, with the latest figure at $454000.0 in Q2 2026.
- Quarterly Capital Expenditures rose 14.65% year-over-year to $454000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 million (up 3.04% YoY) and the FY2025 annual result came in at $1.3 million, down 39.82% from the prior year.
- Capital Expenditures fell to $454000.0 in Q2 2026 per NAUT's latest filing, from $510000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $963000.0 in Q3 2022 and troughed at $219000.0 in Q1 2025.
- A 5-year average of $507166.7 and a median of $472000.0 in 2022 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 256.67% in 2022, down 76.77% in 2022.
- Over 5 years, Capital Expenditures stood at $229000.0 in 2022, then soared by 80.35% to $413000.0 in 2023, then tumbled by 38.5% to $254000.0 in 2024, then retreated by 3.94% to $244000.0 in 2025, then surged by 86.07% to $454000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $454000.0, $510000.0, and $244000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Nautilus Biotechnology | 120.16 Mn | 120.16 Mn | 175,000.00 | 454,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 454,000.00 |
| Jun 30, 2026 | 454,000.00 |
| Mar 31, 2026 | 510,000.00 |
| Mar 31, 2026 | 510,000.00 |
| Dec 31, 2025 | 244,000.00 |
| Dec 31, 2025 | 244,000.00 |
| Sep 30, 2025 | 418,000.00 |
| Sep 30, 2025 | 418,000.00 |
| Jun 30, 2025 | 396,000.00 |
| Jun 30, 2025 | 396,000.00 |
| Mar 31, 2025 | 219,000.00 |
| Mar 31, 2025 | 219,000.00 |
| Dec 31, 2024 | 254,000.00 |
| Dec 31, 2024 | 254,000.00 |
| Sep 30, 2024 | 709,000.00 |
| Sep 30, 2024 | 709,000.00 |
| Jun 30, 2024 | 512,000.00 |
| Jun 30, 2024 | 512,000.00 |
| Mar 31, 2024 | 647,000.00 |
| Mar 31, 2024 | 647,000.00 |